INKT
Mink Therapeutics Inc
$
13.230
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
13.750
Open
13.650
VWAP
13.41
Vol
26.43K
Mkt Cap
59.84M
Low
13.130
Amount
354.29K
EV/EBITDA(TTM)
--
Total Shares
39.37M
EV
56.55M
EV/OCF(TTM)
--
P/S(TTM)
--
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
--
--
-1.160
+65.71%
--
--
-0.885
+42.74%
--
--
-0.855
+71%
Estimates Revision
The market is revising No Change the revenue expectations for MiNK Therapeutics, Inc. (INKT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 9.70%.
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+9.70%
In Past 3 Month
2 Analyst Rating
Wall Street analysts forecast INKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INKT is 39.00 USD with a low forecast of 35.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.230
Low
35.00
Averages
39.00
High
43.00
Current: 13.230
Low
35.00
Averages
39.00
High
43.00
H.C. Wainwright
H.C. Wainwright
Neutral -> Buy
upgrade
$35
2025-08-15
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$35
2025-08-15
upgrade
Neutral -> Buy
Reason
H.C. Wainwright upgraded MiNK Therapeutics to Buy from Neutral with an unchanged price target of $35 post the Q2 report. The firm sees the company's Phase 2 gastric cancer data later this year as a "significant catalyst" for the shares. The majority of patients in the Phase 2 gastric study are now enrolled and initial efficacy data is expected in the back half of the year, the analyst tells investors in a research note. H.C. Wainwright points out MiNK shares are now well below its price target.
H.C. Wainwright
Emily Bodnar
Buy
to
Neutral
downgrade
$35
2025-07-15
Reason
H.C. Wainwright
Emily Bodnar
Price Target
$35
2025-07-15
downgrade
Buy
to
Neutral
Reason
H.C. Wainwright analyst Emily Bodnar downgraded MiNK Therapeutics to Neutral from Buy with a $35 price target.
H.C. Wainwright
H.C. Wainwright
Buy -> Neutral
downgrade
$35
2025-07-15
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$35
2025-07-15
downgrade
Buy -> Neutral
Reason
H.C. Wainwright downgraded MiNK Therapeutics to Neutral from Buy with an unchanged price target of $35 after the company announced that a publication discussing the mechanism of action of CAR-iNKT cells was published in Frontiers in Immunology. With the shares up over 400% since last week, the "majority of the enthusiasm has been priced in for the near-term," the analyst tells investors in a research note. As a result, H.C. Wainwright downgraded MiNK on valuation, It looks to additional updates from the agenT-797 Phase 2 gastric trial in the upcoming months to reevaluate the stock's thesis.
William Blair
Matthew Phipps
Outperform -> Market Perform
downgrade
2025-07-14
Reason
William Blair
Matthew Phipps
Price Target
2025-07-14
downgrade
Outperform -> Market Perform
Reason
William Blair analyst Matthew Phipps late Friday downgraded MiNK Therapeutics to Market Perform from Outperform without a price target after the company announced a publication in Nature's Oncogene describing a patient with treatment-refractory testicular cancer treated with Opdivo plus agenT-797 in the Phase I trial achieved a complete remission. In response to the publication, MiNK shares traded up over 700%, and exceeding William Blair's pervious fair value estimate of $33, the analyst tells investors in a research note. As such, the firm downgraded the stock on valuation ahead of additional data from the ongoing gastric cancer trial. MiNK shares in premarket trading are down 27% to $47.00 after rally 730% on Friday to $64.17.
William Blair
Outperform
to
Market Perform
downgrade
2025-07-11
Reason
William Blair
Price Target
2025-07-11
downgrade
Outperform
to
Market Perform
Reason
William Blair downgraded MiNK Therapeutics to Market Perform from Outperform.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$35
2025-03-18
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$35
2025-03-18
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Mink Therapeutics Inc (INKT.O) is -3.63, compared to its 5-year average forward P/E of -3.06. For a more detailed relative valuation and DCF analysis to assess Mink Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.06
Current PE
-3.63
Overvalued PE
-1.43
Undervalued PE
-4.68
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.14
Current PS
13.23
Overvalued PS
1.50
Undervalued PS
-1.22
Financials
Annual
Quarterly
FY2025Q2
YoY :
+27.11%
-3.69M
Operating Profit
FY2025Q2
YoY :
+56.85%
-4.24M
Net Income after Tax
FY2025Q2
YoY :
+45.21%
-1.06
EPS - Diluted
FY2025Q2
YoY :
-100.00%
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
INKT News & Events
Events Timeline
2025-11-07 (ET)
2025-11-07
09:03:20
MiNK Therapeutics announces new clinical findings for agenT-797
2025-09-29 (ET)
2025-09-29
07:40:51
MiNK Therapeutics names John Holcomb to its board of directors
2025-09-18 (ET)
2025-09-18
07:35:30
MiNK Therapeutics names Hammond as Head of Inflammatory and Pulmonary Diseases
Sign Up For More Events
Sign Up For More Events
News
9.0
11-07NewsfilterPinnedMiNK Therapeutics Announces Lasting Responses and Immune Activation from Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
9.5
11-05NewsfilterMiNK Therapeutics to Announce Q3 2025 Financial Results and Showcase Key Clinical and Corporate Achievements Advancing iNKT Platform Towards Critical Development
9.5
08-14NewsfilterMiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript
Sign Up For More News
People Also Watch
FAQ
What is Mink Therapeutics Inc (INKT) stock price today?
The current price of INKT is 13.23 USD — it has decreased -3.15 % in the last trading day.
What is Mink Therapeutics Inc (INKT)'s business?
What is the price predicton of INKT Stock?
What is Mink Therapeutics Inc (INKT)'s revenue for the last quarter?
What is Mink Therapeutics Inc (INKT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Mink Therapeutics Inc (INKT)'s fundamentals?
How many employees does Mink Therapeutics Inc (INKT). have?
